Product Description: Moxetumomab, a recombinant CD22-targeting immunotoxin, can be used for the research of hairy cell leukemia (HCL)[1][2].
Applications: COVID-19-immunoregulation
Formula: N/A
References: [1]Sohita Dhillon. Moxetumomab Pasudotox: First Global Approval. Drugs. 2018 Nov;78(16):1763-1767./[2]Robert J Kreitman, et al. Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial. J Hematol Oncol. 2021 Feb 24;14(1):35.